LDN-212320 (10 or 20 mg/kg, i.p) significantly attenuates formalin-evoked nociceptive behavior.
LDN-212320 (10 or 20 mg/kg, i.p) significantly reverses formalin-induced impaired hippocampal-dependent behavior. In addition, LDN-212320 (10 or 20 mg/kg, i.p) increases GLT-1 expressions in the hippocampus and ACC.
LDN-212320 (20 mg/kg, i.p) significantly reduced formalin induced-ERK phosphorylation, a marker of nociception, in the hippocampus and ACC.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: |
Mice. |
Dosage: |
10 or 20 mg/kg. |
Administration: |
IP 24 h before the injection of formalin. |
Result: |
Significantly attenuated licking and biting behavior during both phases 1 and 2 in a dose-dependent manner compared to formalin-injected mice.
Significantly (P < 0.01 or P < 0.001) reduced the licking and biting behavior.
Significantly increased preference for the displaced object (F3, 13 = 28.03, P < 0.01) compared to formalin-injected mice.
Significantly (P < 0.001) increased interaction time with the displaced object compared to formalin-injected mice.
|